PrimeRFP - AI-Powered RFP Solutions
PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DB21FD3WW4554979067!ocrevus 300 MG 10 ML VIAL 10ml — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DB20D9127. PoP ended Oct 19, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support
Awarding office
Dms Pharmaceutical Group Inc
Recipient
Oct 19, 2021
PoP end
$359K
Obligated
$359K
Potential
424210
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal
Contract numberSPE2DB21FD3WW
Also listed asSPE2DB20D9127-SPE2DB21FD3WW
AgencyDla Troop Support
Awarding officeDla Troop Support
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentDms Pharmaceutical Group Inc
CAGE1UNB0
UEIPX72BSBQTKJ3
NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVSPE2DB20D9127
Place of performancePARK RIDGE IL
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 27, 2021
PoP end (current)Oct 19, 2021
Obligated$359K
Current value$359K
Potential value$359K

4554979067!OCREVUS 300 MG/10 ML VIAL 10ML is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $359K ($359K obligated). Current period of performance ends Oct 19, 2021. Place of performance: PARK RIDGE IL.

4554979067!OCREVUS 300 MG/10 ML VIAL 10ML

Recompete timing

Public
● Past PoP end (1767 days ago)

Current PoP ended Oct 19, 2021 (1767 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies
Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%
Open full company profile →

Related awards

Same parent · incumbent
SPE2D026F0120
8511978882!OTHER MEDICAL
$248K
Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract SPE2DB21FD3WW?

SPE2DB21FD3WW (4554979067!ocrevus 300 MG 10 ML VIAL 10ml) is a Dla Troop Support award with a potential value of $359K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DB21FD3WW?

Dla Troop Support awarded SPE2DB21FD3WW to Dms Pharmaceutical Group Inc (potential $359K).

Who is the incumbent on SPE2DB21FD3WW?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Oct 19, 2021.

When does Dms Pharmaceutical Group Inc’s SPE2DB21FD3WW come up for recompete?

SCOUT tracks a period-of-performance end of Oct 19, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/SPE2DB21FD3WW